HRP20110776T1 - Stabilizirani farmaceutski sastavi koji sadrže fesoterodin - Google Patents

Stabilizirani farmaceutski sastavi koji sadrže fesoterodin Download PDF

Info

Publication number
HRP20110776T1
HRP20110776T1 HR20110776T HRP20110776T HRP20110776T1 HR P20110776 T1 HRP20110776 T1 HR P20110776T1 HR 20110776 T HR20110776 T HR 20110776T HR P20110776 T HRP20110776 T HR P20110776T HR P20110776 T1 HRP20110776 T1 HR P20110776T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
composition according
fesoterodine
weight
xylitol
Prior art date
Application number
HR20110776T
Other languages
English (en)
Croatian (hr)
Inventor
Arth Christoph
Mika Hans-J�rgen
Komenda Michael
Lindner Hans
Bicane Fatima
Paulus Kerstin
Irngartigner Meike
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110776(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of HRP20110776T1 publication Critical patent/HRP20110776T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20110776T 2006-06-09 2007-06-06 Stabilizirani farmaceutski sastavi koji sadrže fesoterodin HRP20110776T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06011942 2006-06-09
EP06011941 2006-06-09
EP06011943 2006-06-09
PCT/EP2007/055582 WO2007141298A1 (en) 2006-06-09 2007-06-06 Stabilized pharmaceutical compositions comprising fesoterodine

Publications (1)

Publication Number Publication Date
HRP20110776T1 true HRP20110776T1 (hr) 2011-11-30

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110776T HRP20110776T1 (hr) 2006-06-09 2007-06-06 Stabilizirani farmaceutski sastavi koji sadrže fesoterodin

Country Status (37)

Country Link
EP (1) EP2029134B1 (cg-RX-API-DMAC7.html)
JP (2) JP4743321B2 (cg-RX-API-DMAC7.html)
KR (1) KR101316773B1 (cg-RX-API-DMAC7.html)
CN (1) CN101466371B (cg-RX-API-DMAC7.html)
AP (1) AP2416A (cg-RX-API-DMAC7.html)
AR (1) AR061289A1 (cg-RX-API-DMAC7.html)
AT (1) ATE517619T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007255408B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712865B1 (cg-RX-API-DMAC7.html)
CA (1) CA2652712C (cg-RX-API-DMAC7.html)
CR (1) CR10494A (cg-RX-API-DMAC7.html)
CU (1) CU23850B1 (cg-RX-API-DMAC7.html)
CY (1) CY1111934T1 (cg-RX-API-DMAC7.html)
DK (1) DK2029134T3 (cg-RX-API-DMAC7.html)
EA (1) EA015909B9 (cg-RX-API-DMAC7.html)
EC (1) ECSP089010A (cg-RX-API-DMAC7.html)
ES (1) ES2370943T3 (cg-RX-API-DMAC7.html)
GT (1) GT200800276A (cg-RX-API-DMAC7.html)
HR (1) HRP20110776T1 (cg-RX-API-DMAC7.html)
IL (2) IL195732A (cg-RX-API-DMAC7.html)
MA (1) MA30504B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008015736A (cg-RX-API-DMAC7.html)
MY (1) MY146574A (cg-RX-API-DMAC7.html)
NI (1) NI200800318A (cg-RX-API-DMAC7.html)
NL (1) NL2000690C2 (cg-RX-API-DMAC7.html)
NO (1) NO341980B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ572616A (cg-RX-API-DMAC7.html)
PE (2) PE20080331A1 (cg-RX-API-DMAC7.html)
PL (1) PL2029134T3 (cg-RX-API-DMAC7.html)
PT (1) PT2029134E (cg-RX-API-DMAC7.html)
RS (1) RS51973B (cg-RX-API-DMAC7.html)
SI (1) SI2029134T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN08505A1 (cg-RX-API-DMAC7.html)
TW (2) TWI520735B (cg-RX-API-DMAC7.html)
UY (1) UY30394A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007141298A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200806411B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294047A2 (en) * 2008-04-04 2011-03-16 Actavis Group PTC EHF Novel mandelate salt of fesoterodine
IT1392082B1 (it) 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
KR20120014583A (ko) 2009-05-11 2012-02-17 라티오팜 게엠베하 타르타르산 염 형태의 데스페소테로딘
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP2549985A1 (en) * 2010-03-22 2013-01-30 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
US20140199401A1 (en) * 2011-07-04 2014-07-17 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (en) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
US20150182629A1 (en) * 2012-07-02 2015-07-02 Hetero Research Foundation Stable compositions of fesoterodine
KR20250154562A (ko) 2012-11-02 2025-10-28 머레이 앤 풀 엔터프라이지즈, 리미티드 콜히친 유도체의 투여를 통한 심혈관성 병태의 치료 또는 예방
EA037375B1 (ru) 2013-04-16 2021-03-22 Марри Энд Пул Энтерпрайзес Лимитед Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
DK2986280T3 (da) * 2013-04-16 2021-06-14 Murray & Poole Entpr Ltd Formuleringer med langvarig frigivelse af colchicin og fremgangsmåder til brug af samme
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
WO2019206391A1 (en) 2018-04-26 2019-10-31 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
CA3187827A1 (en) * 2020-06-30 2022-01-06 Imbria Pharmaceuticals, Inc. Modified release formulations of modified forms of trimetazidine
JPWO2023145486A1 (cg-RX-API-DMAC7.html) * 2022-01-28 2023-08-03

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253877T3 (es) * 1998-03-03 2006-06-01 SHIONOGI & CO., LTD. Composiciones farmaceuticas que contienen el inhibidor de fosfolipasa((3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1h-indol-4-il)oxi)acetato de sodio.
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
IL220800A (en) 2015-03-31
EP2029134B1 (en) 2011-07-27
ATE517619T1 (de) 2011-08-15
KR101316773B1 (ko) 2013-10-15
CA2652712C (en) 2014-04-01
CN101466371A (zh) 2009-06-24
MY146574A (en) 2012-08-30
NO341980B1 (no) 2018-03-05
AP2008004673A0 (en) 2008-12-31
SI2029134T1 (sl) 2012-01-31
PT2029134E (pt) 2011-11-02
CA2652712A1 (en) 2007-12-13
GT200800276A (es) 2009-06-18
CU23850B1 (es) 2012-10-15
AU2007255408A1 (en) 2007-12-13
AU2007255408B2 (en) 2013-03-14
TNSN08505A1 (fr) 2010-04-14
CU20080235A7 (es) 2011-04-26
CR10494A (es) 2009-01-19
DK2029134T3 (da) 2011-10-17
NI200800318A (es) 2011-01-12
IL195732A0 (en) 2009-09-01
UY30394A1 (es) 2007-11-30
TWI520735B (zh) 2016-02-11
KR20090026135A (ko) 2009-03-11
NZ572616A (en) 2010-11-26
PE20080331A1 (es) 2008-06-19
CY1111934T1 (el) 2015-11-04
MX2008015736A (es) 2009-01-09
HK1128626A1 (en) 2009-11-06
JP2011140498A (ja) 2011-07-21
NO20090141L (no) 2009-01-09
EA015909B9 (ru) 2012-03-30
JP4743321B2 (ja) 2011-08-10
EP2029134A1 (en) 2009-03-04
ZA200806411B (en) 2009-05-27
RS51973B (sr) 2012-02-29
WO2007141298A1 (en) 2007-12-13
ECSP089010A (es) 2009-01-30
CN101466371B (zh) 2011-10-05
AP2416A (en) 2012-06-01
EA200802444A1 (ru) 2009-06-30
TW201336491A (zh) 2013-09-16
NL2000690C2 (nl) 2008-04-01
BRPI0712865B1 (pt) 2021-08-17
JP2009539802A (ja) 2009-11-19
MA30504B1 (fr) 2009-06-01
PL2029134T3 (pl) 2011-12-30
BRPI0712865A2 (pt) 2012-12-18
TWI397409B (zh) 2013-06-01
TW200814992A (en) 2008-04-01
PE20120476A1 (es) 2012-04-20
EA015909B1 (ru) 2011-12-30
AR061289A1 (es) 2008-08-20
IL195732A (en) 2013-09-30
ES2370943T3 (es) 2011-12-23
JP4781489B2 (ja) 2011-09-28
NL2000690A1 (nl) 2007-12-11

Similar Documents

Publication Publication Date Title
HRP20110776T1 (hr) Stabilizirani farmaceutski sastavi koji sadrže fesoterodin
HRP20171518T1 (hr) Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja
JP2009539802A5 (cg-RX-API-DMAC7.html)
ME00189B (me) Preparati sa neprekidnim oslobađanjem
TW200936183A (en) Pharmaceutical compositions
NO20130366A1 (no) Bruk av bindemidler for fremstilling av lagringsstabile formuleringer
JP2010534202A (ja) 安定化した酒石酸トルテロジン製剤
JP2009538912A (ja) インターロイキン−１β変換酵素阻害剤の経口制御放出剤形
CA2873949A1 (en) Dosage forms comprising apixaban and matrix former
WO2009034540A1 (en) Pharmaceutical composition of sevelamer
Idu Effect of the molecular size of carboxymethylcellulose and some polymers on the sustained release of theophylline from a hydrophilic matrix
RS51488B (sr) Farmaceutska formulacija olanzapina
RU2010153977A (ru) Композиции, содержащие euphorbia prostrata, и способ их получения
AU2014368504B2 (en) Gastro-retentive oral pharmaceutical compositions
CN103877056B (zh) 一种氯吡格雷片及其制备方法
CN102349876B (zh) 一种治疗胃溃疡和十二指肠溃疡的药物及其配制方法
AU2006274565B2 (en) Novel controlled release compositions of selective serotonin reuptake inhibitors
US20120258171A1 (en) Composition comprising fesoterodine and fiber
HRP20130225T1 (hr) Formulacija s odgođenim otpuštanjem koja sadrži 3-(2-dimetilaminometilcikloheksil) fenol
JP2003073270A (ja) 安定性および溶出性の良好なプラバスタチンナトリウム錠
KR102018495B1 (ko) 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
CN101103964B (zh) 一种含有非洛地平的缓释制剂及其制备方法
KR101482315B1 (ko) 난용성 약물을 함유하는 팽윤성 위체류 정제 조성물
Mitra et al. Effect of Filler Hydrophilicity on Superdisintegrant Performance and Release Kinetics From Solid Dispersion Tablets of A Model BCS Class II Drug
RU2584653C2 (ru) Фармацевтическая композиция с пролонгированным высвобождением с антипсихотической активностью и способы её получения